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Cancer has long been known to be a disease caused by alterations in the genetic blueprint of cells. In the past decade it has become
evident that epigenetic processes have a function, at least equally important, in neoplasia. Epigenetics describes the mechanisms that
result in heritable alterations in gene expression profiles without an accompanying change in DNA sequence. Genetics and
epigenetics intricately interact in the pathogenesis of cancer (Esteller, 2007). In this review, we paint a broad picture of current
understanding of epigenetic changes in cancer cells and reflect on the immense clinical potential of emerging knowledge of
epigenetics in the diagnosis, prognostic assessment, treatment, and screening of cancer.
British Journal of Cancer (2009) 100, 571–577. doi:10.1038/sj.bjc.6604930 www.bjcancer.com
& 2009 Cancer Research UK
Keywords: epigenetics; methylation; oncology
                                  
BACKGROUND
The most widely studied epigenetic modification is the cytosine
methylation of DNA within the CpG dinucleotide (Jones and
Baylin, 2007). The frequency of the CpG dinucleotide in the human
genome is much less than expected, approximately 2–5%. CpG
dinucleotides are not equally distributed throughout the genome;
instead, they occur in clusters of either large repetitive sequences
(such as rDNA, satellite sequences, or centromeric repeats) or in
short CG-rich DNA stretches, known as ‘CpG islands’, found
preferentially in the promoter region of genes. The majority of
these ‘CpG islands’ are associated with housekeeping genes and
typically occur close to the transcription start site of the gene. Such
CpG islands are normally unmethylated, consistent with the ability
of genes containing these islands within their promoter region to
be transcribed in the presence of necessary transcription factors.
Methylation of cytosine residues within CpG islands is associated
with binding of methyl-binding domain proteins, recruitment of
histone deacetylases (HDACs) and histone methyltransferases,
histone modification, chromatin condensation, and transcriptional
inactivation of the associated genes. The orchestration of
methylation in CpG islands by an assortment of methylating and
demethylating enzymes is thought to provide one of the layers of
epigenetic control of germ-line and tissue-specific gene expression.
In contrast, repetitive genomic sequences that are scattered
throughout the rest of the genome are heavily methylated and it is
speculated that this may have played an important role over the
course of evolution in maintaining the large amount of non-coding
DNA in a transcriptionally inert state and also the silencing of
endoparasitic and retroviral transposons.
Histones, the protein backbone of chromatin, are also important
in epigenetics. Today, they are recognised as being important
translators between genotypes and phenotypes, having a dynamic
function in the regulation of chromatin structure and gene activity.
Understanding the importance of histones in the normal cell and
how this changes in neoplasia is still in its infancy compared with
that of DNA methylation. Histones can be modified by acetylation,
methylation, phosphorylation, sumoylation, and ubiquitination, all
of which fine-tune the accessibility of DNA to transcription factors
and the subsequent protein interactions that determine chromatin
structure. Particular histone tail modifications have been directly
linked to active or repressed transcription. For example, acetyla-
tion of certain N-terminal lysine residues by histone acetyltrans-
ferases (HAT) is associated with actively transcribed regions. The
reverse process of histone deacetylation, catalysed by HDACs,
results in a tighter closed formation of chromatin and suppression
of DNA transcription. These are carefully conducted in conjunc-
tion with CpG island hypermethylation and provide an additional
layer of epigenetic control. Recently, it has been suggested that
histones are involved in establishing and maintaining ‘epigenetic
memory’ (reviewed in Esteller, 2007).
DNA methylation and histone modifications are not isolated
events, but occur in higher-order chromatin structure. We are only
beginning to scratch the surface of understanding how nucleosome
stability is modulated by the complex interplay between histone
modifications and chromatin-binding proteins to fine-tune gene
expression (reviewed in Berger, 2007). The most recently emerged
participant in the epigenetic field is a family of small regulatory
RNAs called microRNAs (miRNAs). The importance of miRNAs in
orchestrating gene expression, primarily by incorporation into a
silencing machinery termed the ‘RISC’ complex, is becoming
evident. Within this complex, miRNAs bind to partially comple-
mentary target sites in the 30-UTR of genes and can direct either
translational inhibition or mRNA degradation. In this way,
repression by miRNAs is one more way in which gene expression
may be modulated outside changes to DNA sequence.
Methods for analysis of the epigenome have classi-
cally utilised bisulphite modification of genomic DNA. The
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dinucleotides is bisulphite sequencing. A frequently used method
for analysis of methylation, for example in DNA isolated from
cancer tissues, is methylation-specific PCR. This technique uses
PCR primers that discriminate between methylated and unmethy-
lated DNA in bisulphite-modified genomic DNA. The methylation
status of individual candidate gene CpG islands can readily be
assessed this way, for example in cancer biopsies and biofluids.
More recently developed methods use immunoprecipitation
to purify methylated DNA, facilitating high-resolution whole-
genome DNA methylation profiling (the DNA methylome)
(Down et al, 2008).
CANCER
Alterations in methylation pattern in cancer
In cancer, the methylation landscape is profoundly distorted.
Human tumours undergo a global overall loss of DNA methylation,
but also acquire hypermethylation at specific promoters (reviewed
in Chuang and Jones, 2007). The underlying mechanisms that
cause these changes are unknown, but there is a suggestion that at
least a subset of DNA methylation changes occur early in tumour
development and may even initiate carcinogenesis.
Two consequences of losses of methylation have been proposed.
First, weakening of transcriptional repression in normally silent
regions of the genome could cause the potentially harmful
expression of silenced genes, for example those imprinted; but
also inserted viral and parasitic transposons. Second, global
demethylation of the cell also affects chromosome stability. This
is exemplified in patients with the rare condition of immunode-
ficiency – centromeric instability syndrome (germ-line mutation of
DNA methylation enzyme DNMT3b), and in the DNMT1 knockout
mouse (Jackson-Grusby et al, 2001). The latter model revealed a
fascinating interaction between hypomethylation and p53. Condi-
tional deletion of DNMT1 resulted in p53-dependent cell death that
could be partially rescued by mutational inactivation of p53.
Further, it was shown that up to 10% of genes were aberrantly
expressed in hypomethylated fibroblasts and that changes in gene
expression (that included growth factor receptors and proteins
involved in signal transduction among others) were cell-type
specific. In an analysis of primary human colorectal carcinomas,
genome-wide demethylation was shown to correlate closely with
chromosomal instability, further strengthening the hypothesis that
there is a direct link between these two factors and the progression
of carcinogenesis (Rodriguez et al, 2006; Figure 1). An earlier study
in prostate cancer suggested a mechanistic association between
genome-wide DNA hypomethylation and alterations on chromo-
some 8 (Schulz et al, 2002).
Concordant with the hypomethylation events, gene-specific
DNA hypermethylation has been shown to occur in all cancers
(Esteller et al, 2001a). Aberrant CpG island methylation has, up to
the present time, been most commonly assessed in genes already
known to be involved in tumour development, especially in
tumour samples that do not harbour genetic alterations of the
gene. This candidate gene approach has identified aberrant
methylation-mediated silencing of genes involved in most aspects
of tumorigenesis and several studies have confirmed that
methylation-associated silencing inactivates tumour suppressor
genes as effectively as mutations and is one of the cancer
predisposing ‘hits’ in Knudson’s classical two-hit model of
carcinogenesis (Garinis et al, 2002), an hypothesis originally
proposed by Jones and Laird (1999). Other genes that have CpG
islands in their promoter region and have been shown to be subject
to aberrant hypermethylation include those whose protein
products are involved in the cell cycle, DNA repair, apoptosis,
cell adhesion, and angiogenesis. In addition to these examples, a
large number of genes are aberrantly methylated in cancers, yet
lack an obvious function relevant to tumorigenesis. For example,
the MYOD1 CpG island is methylated in multiple tumour types. It
is a question of obvious interest as to why such genes are targets
for methylation. This issue has to some extent been resolved by
studies from several groups showing that genes that become
methylated in cancer cells are specifically packaged with nucleo-
somes containing histone H3 trimethylated on Lys27. This
packaging is established in these (unmethylated) CpG island genes
early in development and then maintained in differentiated cell
types by the presence of an EZH2-containing polycomb complex.
In embryonic cells, the polycomb complex mediates reversible
repression of genes involved in differentiation, but in cancer cells,
the presence of the polycomb complex causes recruitment of DNA
methyltransferases. Methylation ensues, leading to permanent
rather than reversible gene silencing (Ohm et al, 2007; Schlesinger
et al, 2007; Widschwendter et al, 2007).
With the development of genome-wide techniques, additional
novel genes that contribute to tumorigenesis are certain to be
identified. A key question is, of course, why specific sequences are
targeted for hypermethylation in a biological milieu that is subject
to global hypomethylation. How are tumour-specific methylation
profiles established? It seems clear that tumours with a particular
phenotype as a result of hypermethylation would have a clonal
selective advantage leading to their increased survival. However,
given that methylation patterns tend to be non-random and
tumour specific (Costello et al, 2000), are there key switches that
trigger the cascade of abnormal methylation patterns? One
suggestion is that the particular combination of oncogenic
transcription factors and the epigenetic machinery target parti-
cular sequences – as implied by the association in vitro of DNMT
and the fusion protein product of pro-myelocytic leukaemia
protein-1 (PML-RAR) and MYC (Croce et al, 2002) but this has not
yet been shown to be a general mechanism of action. Another
possibility is that the ‘local’ hypermethylation of specific tumour
suppressor genes is the result of the role played by the
environment or nutritional status. This hypothesis arose from
the observation that the most heavily methylated tumours are
those that arise from the gastrointestinal tract, presumably due to
exposure to external carcinogens. One must now ask if other
external factors, for example smoking habits or diet, can cause
particular hypermethylation changes to tumour suppressor genes.
Studies in a mouse model of silica-induced lung cancer have
revealed that epigenetic silencing of p16
INK4a is an early event in
the progression of lung cancer (at the stage of moderate dysplasia)
(Blanco et al, 2007). Further study of this area, attempting to show
a direct causal relationship between chemical damage, hyper-
methylation, and commitment to a pathway leading to lung
carcinogenesis would clearly be interesting.
The most likely candidates for ‘key epimutations’ that may
commit cells to carcinogenesis are the DNA repair genes.
For example, epigenetic silencing of BRCA1 results in the inability
of cells to repair double-stranded DNA breaks, thereby relying
on a more error-prone pathway that may result in the accumula-
tion of mutations, potentially leading to cancer. The hMLH1
mismatch repair gene is another well-characterised system of
DNA repair. Deficiencies of this system result in mutation rates
100-fold greater than normal cells. In 90% of sporadic cases of
colorectal, endometrial, and gastric cancers, which exhibit micro-
satellite instability but without a germ-line mutation in hMLH1,
the gene is epigenetically inactivated (Herman et al, 1998),
implying that a single epigenetic event may unleash new mutator
pathways.
Histone modifications in cancer cells
We are still largely ignorant of the intricate workings of histone
packaging and its dynamic modulation of chromatin, and how
Context and potential of epigenetics in oncology
J Lopez et al
572
British Journal of Cancer (2009) 100(4), 571–577 & 2009 Cancer Research UKthese are disrupted in cancer. Preliminary attempts at profiling
histone modifications on a genome level in a range of cell lines
suggest that cancer cells exhibit a loss of monoacetylated and
trimethylated forms of histone H4 (Fraga et al, 2005). Much work
is ongoing to try to decode the histone map as well as understand
how the complex interplay between histone modifications and
DNA methylation is dysregulated in cancer. However, a mouse
model of carcinogenesis has shown a few fascinating insights about
the working of histones. Histones are present early-on in
tumorigenesis and accumulate (Fraga et al, 2004) – suggesting
that they too may have a function in the progression/transforma-
tion of neoplasia. Given the function histones may have in
maintaining stable epigenetic memory, unravelling the workings of
this process, and elucidating how it could be reverted or
re-programmed to its ‘normal’ setting may open up therapeutic
avenues for the future.
Dysregulation of miRNAs
Global analysis of miRNA expression levels in several cancer types
has shown that many miRNAs are also deregulated and may act as
tumour suppressors. For example, deletion of mir-16 in chronic
lymphocytic leukaemia leads to upregulation of one of its targets,
the anti-apoptotic oncogene, BCL2 (Cimmino et al, 2005), whereas
miRNA Let-7a-2 normally targets RAS and is downregulated in
lung cancer (Takamizawa et al, 2004). Hypermethylation of CpG
islands associated with specific miRNAs has, therefore, been
proposed as one of the mechanisms by which the miRNA is
selectively downregulated in tumours. Furthermore, in cases where
the miRNA is situated in the coding region of a gene, methylation
may simultaneously suppress expression of both the protein-
coding gene and also its embedded miRNA.
TRANSLATIONAL EPIGENOMICS
Epigenomic profiles as cancer cell markers
Methylated genomic DNA has several properties that make
it an attractive potential biomarker in oncology. First, hyper-
methylation of most genes is rarely found in healthy individuals,
although some changes may occur with age and environmental
stresses. As such, the majority of methylation changes detected in
cancer cells are acquired during neoplastic development and,
therefore, specific to cancer. Second, methylated DNA is chemi-
cally stable and assays to detect it are highly sensitive and
increasingly user friendly. DNA methylation assays can be
performed on small biopsy samples obtained during the routine
diagnostic work-up of patients, on archived frozen or paraffin-
embedded tissue, and on the soluble genomic DNA found in the
peripheral blood and other biofluids of many cancer patients
(Table 1).
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Figure 1 Current understanding of some of the changes to DNA and chromatin that occur in cancer cells. In the normal cell, promoters of actively
transcribed genes are unmethylated and found within regions of euchromatin. Expression of other genes is repressed by promoter methylation and
heterochromatin formation. In cancer, this is deregulated, resulting in the aberrant expression of normally silent genes and repression of tumour suppressor
genes. Abbreviations: HAT, histone acetyltransferase; SWI/SNF, switch/sucrose nonfermentable nucleosome remodelling complex; MeCP2, methyl CpG-
binding protein 2; HDAC, histone deacetylase.
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and prognostic assessment of patients, would be a validated,
specific, and sensitive panel of methylation markers that identifies
individual cancer types. Thus far, only best-guess selections of a
panel of candidate genes have been used. With the development of
genomic techniques and an expansion in our understanding of the
normal and diseased ‘methylome’, the prospect of a diagnostic
methylation signature for each subtype of cancer becomes a
genuine possibility.
Tumour-cell-derived DNA present in ‘luminal’ secretions, for
example in saliva, sputum, gastrointestinal fluids, ductal lavage
fluid, bronchoalveolar fluid, and pleural fluid, will offer an
alternative source for methylation analysis. For example, a
methylation screening panel of five candidate genes has been
proposed to distinguish between malignant mesothelioma, pri-
mary lung adenocarcinoma, and normal lung (Tsou et al, 2005).
Such a resource would be very valuable for respiratory clinicians to
differentiate between lung cancer subtypes, each with its own
distinct treatment regimen, when biopsies are difficult to obtain or
persistently yield very small amounts of tissue. A significant
proportion of diagnostic biopsies, often harvested from sites of
metastatic disease, are reported as ‘undifferentiated carcinoma of
unknown origin’. Such cancers frequently evade even the most
skilled histopathologist and rigorous immunocytochemical analy-
sis often fails to pinpoint the primary site. In these difficult
diagnostic situations, where prognosis and treatment may vary
widely between possible cancer types, a definitive methylation
signature would be extremely useful in guiding management. It
may even be possible to obtain such a signature from peripheral
blood. Interestingly, it has been suggested that hypomethylation of
L11 LINE sequences is particularly prevalent in urothelial cancers
and might have diagnostic utility in these cancers (Ju ¨rgens et al,
1996). In a large case–control study, it has now been shown by
measurement of the degree of global methylation in genomic DNA
(using peripheral blood leukocytes) that DNA hypomethylation is
indeed associated with increased risk of developing bladder cancer
(Moore et al, 2008). Furthermore, this association is independent
of smoking and the other risk factors for urothelial neoplasia.
Assessment of global hypomethylation could therefore be a useful
biomarker of susceptibility to urothelial (and perhaps other)
cancer types.
Screening
Hypermethylation of tumour suppressor genes is readily detect-
able in pre-malignant lesions, consistent with the hypothesis that
epigenetic change occurs early in neoplasia. For example, CpG
island hypermethylation is seen in p16
INK4a, p14
ARF, and MGMT in
colorectal adenomas (Judson et al, 2006); and MLH1 aberrant
methylation in atypical endometrial hyperplasia (Banno et al,
2006). It is, therefore, entirely conceivable that DNA methylation
may come to play a role in early detection screening. In this
respect, the presence of methylated genomic DNA in a number of
biofluids, as noted above, offers the possibility of non-invasive
molecular screening for many common malignancies (Table 1).
The major challenge in developing this approach will be the
difficulties in achieving the high degree of sensitivity and
specificity required. This is illustrated in a study of detection
and quantification in serum of mutations in the APC gene in
patients with colorectal cancer (Diehl et al, 2005). In the first
instance, detection of methylated DNA in serum may be
particularly helpful in individuals with a high familial risk of
cancer. A careful study of methylation patterns of a panel of 10
candidate genes in inherited and sporadic breast and colorectal
cancers showed that hereditary cancers ‘mimic’ the DNA
methylation patterns present in the sporadic tumours (Esteller
et al, 2001b), suggesting the development of a validated screening
profile for a particular cancer, for example breast cancer, that will
have great utility in management of high-risk patients in family
history clinics. Hand in hand with screening is the potential for
guiding early treatment strategies. In cervical cancer, different
methylation events have been linked to distinct stages of HPV-
induced malignant transformation in cell lines (Henken et al,
2007). Thus, the early detection of methylation signatures in
cervical smears not only allows diagnosis of pre-malignant lesions,
but also offers the potential for epigenetic therapies to be used
upfront to reverse/prevent transformation.
Epigenomic profiles as markers of tumour prognosis
To supplement traditional cancer prognosis methodologies, such
as the classical TNM system that assesses tumour size, lymph node
involvement, and distant metastasis, methylation patterns are now
Table 1 Studies of DNA-methylation-based tests in biofluids
Biofluid Methylated genes Clinical parameter Reference
Serum p16
INK4a Detection (liver) Wong et al (1999)
GSTP1 Detection (prostate) Goessl et al (2000)
Multiple Detection (head and neck) Sanchez-Cespedes et al (2000)
p16
INK4a Detection (oesophagus) Hibi et al (2001)
Multiple Detection (gastric) Lee et al (2002)
hMLH1 Chemosensitivity (ovarian) Gifford et al (2004)
NGFR Detection (colorectal) Lofton-Day et al (2008)
SEPT9 Detection (colorectal) Lofton-Day et al (2008)
TMEFF2 Detection (colorectal) Lofton-Day et al (2008)
Sputum p16
INK4a Detection (lung) Belinsky et al (2002)
hMLH1, hMSH2 Detection (lung) Wang et al (2003)
Urine GSTP1 Detection (prostate) Goessl et al (2000)
GSTP1 Detection (prostate) Cairns et al (2001)
Multiple Detection (renal) Hoque et al (2004)
Multiple Detection (prostate) Vener et al (2008)
Faeces SFRP2 Detection (colorectal) Mu ¨ller et al (2004)
Vimentin Detection (colorectal) Chen et al (2005)
Semen GSTP1 Detection (prostate) Goessl et al (2000)
Saliva Multiple Detection (head and neck) Carvalho et al (2008)
Blood cells GSTP1 Detection (prostate) Goessl et al (2000)
Multiple Breast cancer risk Widschwendter et al (2008)
IGF2 Colorectal cancer risk Cui et al (2003)
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Several small studies have used cluster analysis to link methylation
patterns to specific clinical parameters. As additional methylated
genes are identified and their prognostic utility revealed, this is
likely to be an active area in the coming years. It is entirely
foreseeable that clinicians will be making decisions on adjuvant
treatment based on specific methylation signatures that specifically
assess the ‘metastatic’ potential of an early cancer. A number of
studies attest to the utility and clinical applicability of this
approach. For example, detection of methylated DNA from the
MYOD1 CpG island is associated with reduced disease-free and
overall survival in cervical cancer (Widschwendter et al, 2004).
Similarly, detection of circulating methylated DNA in the serum of
patients with melanoma has prognostic value (Mori et al, 2005).
The other area in which epigenetics has great clinical potential is
in the early detection of cancer relapse in routine patient follow-
up. Serial analysis of serum or biofluid DNA methylation patterns
may one day enable the detection of early relapse before it
manifests with clinical symptoms or on routine imaging, affording
an extended window in which cure may still be achievable. One
small prospective study has already shown that gene methylation
(panel of 10 genes) in saliva is a promising biomarker for the
follow-up and early detection of still curable relapses of head and
neck squamous cell carcinoma patients (Righini et al, 2007).
Pharmacoepigenomics: epigenomic profiles as a marker of
response to chemotherapy
The most exciting prospect for an oncologist is that methylation
profiling may have utility in predicting the sensitivity of individual
cancers to anti-cancer agents. The most compelling evidence for this
is provided by the methylation-associated silencing of the DNA repair
protein MGMT in glioblastomas. Hypermethylation of MGMT is the
best independent predictor of response to temozolomide in gliomas
(Hegi et al, 2005). Another example of a gene whose methylation-
associated silencing is associated with relative drug resistance is the
DNA mismatch repair gene hMLH1.L o s so fhMLH1 is associated
with increased resistance to platinum compounds in vitro (Strathdee
et al, 1999) and acquired methylation (detectable in peripheral blood)
during treatment predicts poorer outcome following chemotherapy
for ovarian cancer (Gifford et al, 2004).
Therapeutic targets
Recently, increasing evidence supports the hypothesis that
acquired resistance to chemotherapy results from progressive
accumulation of epigenetic changes (Glasspool et al, 2006) and this
inevitably leads to the question of whether these changes are
reversible. Studies in vitro and in model systems certainly suggest
that treatment with demethylating agents can reverse drug
resistance (Plumb et al, 2000). These and other observations,
particularly the recognition that epigenetic changes are the
mechanisms affecting several aspects of tumour cell biology,
including cell growth, cell-cycle control, differentiation, DNA
repair, and cell death, strongly support the rationale for reversal of
methylation as an effective treatment strategy for cancer.
Demethylating agents
In cancer cell lines, demethylating agents, such as 5-azacytidine
and decitabine that inhibit DNMTs, effectively switch on expres-
sion of previously silenced genes. The greatest success achieved
with demethylating agents thus far has been in the treatment of
haematopoietic malignancies, particularly acute myeloid leukaemia
and myelodysplasia. Both of these malignancies have been associated
with hypermethylation of numerous genes, including p15
INK4B,w h i c h
in clinical studies has been reported to be aberrantly methylated in
450% patients. Analysis of a small cohort of 23 myelodysplastic
syndrome (MDS) patients with hypermethylated p15
INK4B demon-
strated a reduction in methylation following one course of low-dose
5-azacytidine and this was associated with clinical response
(Daskalakis et al, 2002). This not only shows proof of principle,
but also opens up the horizon for a number of exciting possibilities.
Recent data have implicated alterations in methylation of the
p15
INK4B gene in the transformation of MDS to acute myeloid
leukaemia (Aggerholm et al, 2006). Reversing this epigenetic change
may well reduce the risk of leukaemic transformation. Of course,
despite these promising initial observations, there are several
disadvantages associated with the clinical use of demethylating
agents. First, demethylating agents have thus far a less impressive
clinical track record in solid tumours than in haematological
malignancies. This may be predominantly attributable to toxicity,
although this is now felt to be due to less than optimal doses and
scheduling. However, an innovative phase I study recently used
demethylation agents as a ‘priming’ agent before the administration
of chemotherapy with encouraging results. The combination was
well tolerated, and pharmacodynamic end points of demethylation of
specific target genes were met (Appleton et al, 2007). A significant
proportion of cells in many solid tumours are non-proliferating at
any given time. Demethylating agents selectively target replicating
cells. As a result, this may be a limitation to the utility of the current
generation of demethylating agents in non-haematological malig-
nancies. Finally, the clinical outcome of treatment with demethylat-
ing agents may be dependant on the specific profile of methylated
genes present in any individual cancer. For example, as described
above, methylation of the MGMT gene in primary brain tumours
confers sensitivity to temozolomide. Reversal of methylation in this
gene would result in increased resistance to temozolomide, one of
the few drugs with meaningful activity in this disease.
HDAC inhibitors (HDACi)
Histone deacetylase inhibitors are novel agents that inhibit HDAC –
the enzyme responsible for the removal of acetyl groups from
specific residues on histone chains. Histone deacetylase inhibitors
affect acetylation of a wide variety of proteins in cells and their
precise mechanism of action as anti-tumour agents has not been
definitively established. However, an attractive model proposes that
HDACi affect transcription by promoting acetylation of histones –
resulting in a more relaxed chromatin structure in part by chromatin
remodelling and by changes in the structure of proteins in
transcription factor complexes (Xu et al, 2007). The net result is
reactivation of silenced genes in various pathways of tumour
suppression. Early clinical studies showed substantial activity of
HDACi in relapsed and refractory cutaneous T-cell lymphoma
(Mann et al, 2007) at doses that caused hyperacetylation of
peripheral blood mononuclear cells. Active investigation is ongoing
in a variety of other tumour model systems. Combining demethylat-
ing agents with HDACi and then with cytotoxic therapy is a rational
progression because epigenetic treatments could offer improved
access for cytotoxic agents to the target DNA/protein complex thus
allowing them to work synergistically. Numerous laboratory studies
have confirmed this approach and it is making its way to the clinic.
miRNAs
As our understanding of the function of microRNAs in tumor-
igenesis expands, their potential as therapeutic targets becomes
ever more intriguing. Treatment of cultured cells in vitro with
demethylating agents, either alone or in combination with HDACi,
has been shown to re-activate expression of tumour suppressor
miRNAs, such as miRNA-124a and mir-127, causing the corre-
sponding repression of their oncogenic targets (Saito et al, 2006).
To the sceptic who worries that epigenetic treatments may be too
‘blunderbluss’, miRNA-based designer therapies may prove to be
the answer. Although the successful delivery of siRNAs to solid
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to mimic tumour suppressor miRNAs could be a potential method
of selectively repressing the expression of oncogenes.
CONCLUSION
The next decade promises many advances in our understanding of
the normal human methylome and its intricate workings,
particularly in its interactions with the environment and how this
may be deranged in cancer, and even more excitingly, how this
may be exploited as therapy. The age in which epigenetics becomes
an essential component in the clinical management of the oncology
patient is getting closer.
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